We are a biotechnology company dedicated to developing allogeneic CAR-T cell therapies for the treatment of refractory diseases, with a primary focus on advanced solid tumors. Compared to traditional small molecule and large molecule biologics, cell therapies hold the potential to deliver breakthroughs in diseases remain clinically untreatable.
| Code | Target | Indication | Combination | Early study | CMC | Pre-clinical | IIT | IND | Phase 1 | Phase 2 |
| MT020 | CD19 | AID | ||||||||
| MT026 | IL13Rα2 | Recurrent Gliomas | ||||||||
| MT027 | B7-H3 | Recurrent Gliomas | ||||||||
| Recurrent Gliomas | +Bevacizumab | |||||||||
| First Diagnosis of Glioma | Adjuvant Therapy | |||||||||
| Thoracic Mesothelioma | ||||||||||
| Brain Metastases | ||||||||||
| Abdorminal Metastases |
In 2025, with the strong support of governments at all levels, investment institutions and industrial partners, T-MAXIMUM Biotech will continue to promote technological innovation and industrialization process, taking breakthrough universal CAR-T technology as the foundation.
[Yokohama, Japan - August 8, 2024] - At the highly anticipated 2024 ASCO Breakthrough Summit, T-MAXlMUNM Biotech, which focuses on the development of universal cell drugs, It has been highly praised by the international medical community for its pioneering achievements in the field of allo…
On November 4th, the first event of the "Suzhou Biomedical Collaborative Innovation Enhancement Action Plan" - a symposium in the field of cell therapy - was successfully held.